USANA Health Sciences Inc. - 10-Q Summary
Business Context and Reporting Period
Company: USANA Health Sciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: October 2, 2010 (Third Quarter of Fiscal Year 2010)
Business Model: USANA develops, manufactures, and distributes nutritional and personal care products via a global network marketing system of independent distributors ("Associates").
Key Financial Metrics
| Metric | Q3 2010 | Q3 2009 | 9 Months 2010 | 9 Months 2009 |
|---|---|---|---|---|
| Net Sales | $135.0 million | $110.8 million | $380.1 million | $320.2 million |
| Gross Profit | $109.8 million (81.4% margin) | $88.1 million (79.6% margin) | $309.2 million (81.3% margin) | $253.9 million (79.3% margin) |
| Net Earnings | $12.8 million | $7.9 million | $33.3 million | $23.3 million |
| Diluted EPS | $0.79 | $0.51 | $2.11 | $1.51 |
| Cash & Equivalents | $22.9 million | $13.3 million (end of Q3 2009) | N/A | |
| Operating Cash Flow (9mo) | $46.2 million | $20.5 million | ||
| Debt (Line of Credit) | $19.0 million | $0 (Short-term) | N/A |
Note: All figures in millions unless otherwise noted. Debt balance reflects a $19.0 million drawdown on a $40.0 million facility as of Oct 2, 2010.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 21.9% in Q3 2010 compared to Q3 2009. This was driven by a 48.7% increase in Asia Pacific sales, largely due to the acquisition of BabyCare Ltd. and growth in Hong Kong.
- Profitability: Net earnings rose 62.4% in Q3 2010. Gross margin improved to 81.4% due to lower raw material costs, currency benefits, and price increases on flagship products.
- Acquisition Impact: On August 16, 2010, USANA acquired BabyCare Ltd. (a Chinese direct selling company) for $62.7 million ($45M cash, $17.7M stock). BabyCare contributed $3.4 million in sales and 10,000 active associates in Q3.
- Customer Base: Total active Associates increased 17.6% to 234,000. While North America saw a decline in active associates (-10.8%), Asia Pacific grew 47.4%.
- Expense Management: Associate incentives decreased as a percentage of sales to 44.9% in Q3 2010 from 45.9% in Q3 2009, despite higher absolute sales volumes.
Guidance, Outlook, and Risks
Management Commentary:
- Management expects Associate incentives expense to continue declining relative to sales in the fourth quarter.
- The company anticipates sales growth acceleration in China once USANA products are registered and approved for sale in the market.
- Share repurchases continued, with 199,000 shares retired in the first nine months of 2010. The Board authorized an additional $40.0 million for repurchases in Q3.
Risks and Contingencies:
- China Regulatory Risk: Significant uncertainty regarding Chinese laws governing direct selling, foreign investment, and labor. BabyCare operates under a single-level compensation model due to Chinese restrictions on multi-level marketing.
- Currency Fluctuation: 70.1% of sales in the first nine months of 2010 were outside the U.S. A strengthening U.S. dollar negatively impacts reported sales and earnings.
- Debt Covenants: The $40 million line of credit matures in May 2011. The company must maintain adjusted EBITDA of at least $50 million and a debt-to-EBITDA ratio of 2.5:1.
- Legal Proceedings: A class action lawsuit filed in Nevada in 2009 was dismissed with prejudice in September 2010.
Investor Verification Checklist
- Acquisition Integration: Verify the timeline and regulatory approval status for introducing USANA products into the Chinese market via BabyCare.
- Debt Maturity: Confirm the company's ability to refinance or repay the $19.0 million line of credit maturing in May 2011.
- North America Trends: Monitor the continued decline in active Associates in North America and its impact on long-term revenue stability.
- China Compliance: Review ongoing compliance with Chinese direct selling regulations and labor laws, which pose significant operational risks.
- Currency Exposure: Assess the impact of potential U.S. dollar strengthening on future earnings, given the high percentage of international sales.